ClinicalTrials.gg
Active, not recruitingNCT04846478Updated Nov 19, 2026Results posted

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

A Phase 1 interventional study of Talazoparib and Tazemetostat in Metastatic Prostate Cancer and Metastatic Castration-resistant Prostate Cancer, sponsored by Dana-Farber Cancer Institute. Active, not recruiting at 2 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Dana-Farber Cancer Institute · Phase 1, Interventional, and Treatment

How we know

Updated Nov 19, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies testing talazoparib in Prostatic Neoplasms — 4 open to participants now, 7 under way, 1 of them phase 3. talazoparib · Prostatic Neoplasms.

Enrollment
8th of 11
35 · median 70
Started
2021
with 3 others
Phase 1
2 of 11
none open now
Registered
8th of 11
by date
Lead sponsor
1 of 11
Dana-Farber Cancer Institute

Among the 11 studies testing talazoparib in Prostatic Neoplasms, this one is the 8th largest by enrollment, is one of 4 that started in 2021, is one of 2 in phase 1, and was the 8th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 11 studies testing talazoparib in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About talazoparib

talazoparib: first FDA approval 2018 (TALZENNA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing talazoparib in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This trial is testing whether molecularly targeted oral medications called talazoparib and tazemetostat can be safely combined for the treatment of prostate cancer, and whether the combination is effective in shrinking or preventing the growth of metastatic prostate cancer.

The names of the study drugs involved in this study are:

  • Talazoparib
  • Tazemetostat
Read the detailed description

This is a Phase 1a/1b clinical trial to assess safety, tolerability and preliminary clinical activity of the combination of talazoparib with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC) patients.

The U.S. Food and Drug Administration (FDA) has not approved talazoparib or tazemetostat for metastatic castration-resistant prostate cancer (mCRPC) but they have been approved for other uses. Talazoparib has been approved for use in breast cancer, and tazemetostat has been approved for use in certain types of sarcoma and lymphoma.

Talazoparib is an orally administered molecularly targeted chemotherapy drug called a "PARP inhibitor", which acts to block the ability of cancer cells to repair certain forms of damage to their DNA - the accumulation of damaged DNA causes certain cancer cells to die. Other PARP inhibitors are already approved for use in prostate cancer patients with specific gene mutations detected in their blood or in their cancer, and talazoparib is currently being studied for treatment of prostate cancer in other clinical trials.

Tazemetostat is an orally administered molecularly targeted chemotherapy drug called an "EZH2 inhibitor", which acts to block the production of proteins encoded by DNA in the cancer cells that are important in cancer growth and survival. Tazemetostat is also being studied for the treatment of prostate cancer in other clinical trials. In the laboratory setting, tazemetostat causes changes in protein levels in prostate cancer cells that make them sensitive to dying in the presence of PARP inhibitors.

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

The study design involves two parts. The first part is called the "dose escalation" to find a safe dose for the combination of talazoparib and tazemetostat. The second part is called the "dose expansion" where additional participants are treated at the safe dose identified in the first part of the study.

Participants will receive study treatment for as long as they do not have serious side effects and their disease does not get worse. Participants will be followed after completion of study treatment for up to 24 months.

It is expected that about 38 people will take part in this research study.

Funding for this research is provided by a grant awarded by the non-profit Prostate Cancer Foundation along with Pfizer, Inc. In addition, Pfizer is supporting the study by providing the study drug talazoparib. Epizyme, Inc. is supporting the study by providing the study drug tazemetostat.

03

Conditions studied

  • Metastatic Prostate Cancer
  • Metastatic Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • Metastatic Prostate Cancer
  • Metastatic Castration-resistant Prostate Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have or cytologically confirmed prostate cancer (code 10036910) with progressive disease at the time of study entry by either

    • Sequence of at least 2 rising PSA values at a minimum of 1-week intervals
    • Radiographic progression per RECIST1.1 for soft tissue and/or per PCWG3 for bone, with or without PSA progression
  • Patients must have disease by bone scintigraphy or other nodal or visceral lesions on CT or MRI with a bone or soft tissue lesion amenable to image-guided percutaneous , a castrate level of testosterone (\<50ng/dL), and evaluable for disease response by either

    • Baseline PSA ≥ 2.0 ng/mL OR
    • per 1.1 NOTE: Subjects must maintain a castrate state. If they have not had an orchiectomy, they must continue to receive LHRH or GnRH agonists or antagonists unless intolerant.
  • Past progression on at least one novel hormonal therapy (abiraterone, enzalutamide, apalutamide, darolutamide, galeterone, orteronel, seviteronel or equivalent) in either the hormone-sensitive or castration-resistant disease setting.
  • Not a candidate for docetaxel or cabazitaxel chemotherapy due to:

    • progression within 12 months of completion or intolerance to prior taxane OR
    • refusal of taxane OR
    • to, or lack of fitness for taxane OR
    • investigator assessment that taxane is not clinically indicated or preferred
  • Age ≥18 years. Children under 18 are excluded from this study as prostate cancer is a disease of adults
  • performance status ≤1 ( ≥70%, see Appendix A).
  • Participants must have adequate organ and marrow function as defined below:

    • leukocytes ≥ 3,000/mcL
    • ≥1,500/mcL
    • ≥9 g/dL (without transfusion or growth factor in prior 28 days)
    • ≥ 100,000/mcL (without transfusion of growth factor in prior 28 days)
    • total ≤ 1.5 × institutional (ULN) unless known or suspected Gilbert syndrome
    • (SGOT)/ALT(SGPT) ≤ 3 × institutional ULN
    • (GFR) ≥60 mL/min/1.73 m2 (based on formula OR creatinine clearance based on 24 hour urine collection)
  • (HIV)-infected participants on effective anti-retroviral therapy (with no known or predicted drug-drug interactions with talazoparib and/or tazemetostat) with undetectable viral load within 6 months are eligible for this trial.
  • For participants with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable. If suppressive therapy is indicated, there must be no known or predicted drug-drug interactions with talazoparib and/or tazemetostat.
  • Participants with a history of virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if there are no known or predicted drug-drug interactions with talazoparib and/or tazemetostat and they have an undetectable HCV viral load.
  • Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Functional Classification. To be eligible for this trial, participants should be class 2B or better.
  • Prior treatment with a PARP inhibitor is allowed.
  • Planned to undergo core biopsy of a recurrent/metastatic lesion adequate for next generation sequencing (NGS) after trial registration but prior to cycle 1 day 1 of therapy. Confirmation of adequacy of this biopsy material for NGS is NOT required for initiation of therapy. If elective biopsies are not being performed at the treating institution due to preparations or precautions related to COVID-19, this requirement can be waived on discussion with the trial PI.
  • Willing to undergo core biopsy of a recurrent/metastatic lesion adequate for next generation sequencing (NGS) after 8 weeks (+/- 7 days) of study treatment.
  • The effects of talazoparib and tazemetostat on the developing human fetus are unknown. For this reason and because oral chemotherapeutic agents are known to be teratogenic, men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of talazoparib and tazemetostat administration.
  • Ability to swallow oral medications.
  • Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Participants who have had chemotherapy, intravenous experimental agent, radiopharmaceutical therapy or radiotherapy within 4 weeks prior to planned cycle 1 day 1 of study treatment.
  • Participants who have received oral anti-neoplastic intervention such as an oral hormonal agent, PARP inhibitor, or oral experimental agent within 14 days prior to planned cycle 1 day 1 of study treatment.
  • Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have clinically significant residual toxicities > Grade 1) except for stable complications of prior procedures (such as urinary incontinence or erectile dysfunction) or Grade 2 anorexia, alopecia, neuropathy, and fatigue, for which resolution is not required.
  • Participants who are receiving any other agents.
  • Participants previously treated with an inhibitor of EZH2.
  • Patients with known or should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to talazoparib or tazemetostat.
  • Participants receiving the following concurrent medications:

    • Participants receiving the P-gp inhibitors amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil are ineligible. Participants receiving other P-gp inhibitors are not excluded but should be monitored for potential increased adverse reactions.
    • Participants receiving BCRP inhibitors are not excluded but should be monitored for potential increased adverse reactions.
    • Participants receiving any medications or substances that are strong or moderate inhibitors or inducers of are ineligible.
    • Precaution is warranted with concomitant use of agents with a narrow therapeutic index that are substrates of CYP3A4 and/or P-gp.

Because the lists of these agents are constantly changing, it is important to regularly consult a frequently updated medical reference. As part of the enrollment/ procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.

  • Participants with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
  • Participants with psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant and nursing women are excluded from this study because they do not develop prostate cancer.
  • Arterial or venous thromboembolic event within the last 3 months.
  • Concurrent active . Patients with non-melanomatous skin cancer, superficial bladder cancer, cancer not needing active therapy for at least 2 years, cancer for which the treating investigator deems the subject to be in remission, or any prior malignancy that was treated with curative intent (no evidence of disease for at least 3 years) are also permitted to enroll.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Dose Escalation Talazoparib + Tazemetostat

    Standard 3+3 dose escalation will be followed, participants will initially receive talazoparib and tazemetostat at a dose of 75% of the starting dose for their FDA-approved indications. During each 28 day study treatment cycle participants will take: * Talazoparib once daily. * Tazemetostat twice daily.

    Drug: Talazoparib · Drug: Tazemetostat

  • Experimental
    Dose Expansion Talazoparib + Tazemetostat

    Participants will receive talazoparib and tazemetostat at the safe dose identified in the first part (dose escalation) of the study. During each 28 day study treatment cycle participants will take: * Talazoparib once daily. * Tazemetostat twice daily.

    Drug: Talazoparib · Drug: Tazemetostat

Interventions

  • capsule, taken by mouth, once a day

    Also known as: Talzenna

  • orally as a tablet twice daily.

    Also known as: Tazverik, EPZ-6438

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicity (DLT)

    Assessed by the investigator, based on toxicity grade (according to the National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] v5.0), clinical significance, and possible relationship to either study drug.

    Time frame: Up to 28 days after treatment start (cycle 1)

  2. Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0

    A treatment related toxicity event is defined as any adverse event that is deemed to "'Definitely', 'Possibly', 'Probably' related to either of the study drugs. All adverse events are assessed by CTCAE Version 5.0.

    Time frame: Up to 2 years from treatment start

Secondary outcomes

  1. Overall Response Rate (ORR) in Patients Treated With the Recommended Phase 2 Dose (RP2D)

    Overall response included objective response or prostate-specific antigen (PSA) response. Objective response was assessed by the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT/MRI: including Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Objective Response = CR + PR. PSA response was defined as ≥ 50% decline from cycle 1 day 1 value. PSA response was assessed in patients with measurable PSA only (≥ 2 ng/mL on cycle 1 day1).

    Time frame: Enrollment up to 2 years

07

Results

Posted Nov 19, 2026

Participant flow

Participant flow — Overall Study
MilestoneDose Escalation: Dose Level 0Dose Escalation: Dose Level 1Dose Escalation: Dose Level 2Dose Expansion: Dose Level 1
Started37220
Completed0000
Not completed37220
Withdrew: Radiographic changes with rising psa1112
Withdrew: Unconfirmed radiographic progression2101
Withdrew: Adverse event0101
Withdrew: Radiographic progression04111
Withdrew: Clinical/symptomatic disease progression0003
Withdrew: Physician decision0002

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicity (DLT)

Assessed by the investigator, based on toxicity grade (according to the National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] v5.0), clinical significance, and possible relationship to either study drug.

Time frame:
Up to 28 days after treatment start (cycle 1)
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicity (DLT)
ParticipantsDose Escalation: Dose Level 0Dose Escalation: Dose Level 1Dose Escalation: Dose Level 2Dose Expansion: Dose Level 1
Number of Participants With Dose Limiting Toxicity (DLT)011—
PrimaryNumber of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0

A treatment related toxicity event is defined as any adverse event that is deemed to "'Definitely', 'Possibly', 'Probably' related to either of the study drugs. All adverse events are assessed by CTCAE Version 5.0.

Time frame:
Up to 2 years from treatment start
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0
ParticipantsDose Escalation: Dose Level 0Dose Escalation + Expansion (RP2D): Dose Level 1Dose Escalation: Dose Level 2
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.03272
SecondaryOverall Response Rate (ORR) in Patients Treated With the Recommended Phase 2 Dose (RP2D)

Overall response included objective response or prostate-specific antigen (PSA) response. Objective response was assessed by the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT/MRI: including Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Objective Response = CR + PR. PSA response was defined as ≥ 50% decline from cycle 1 day 1 value. PSA response was assessed in patients with measurable PSA only (≥ 2 ng/mL on cycle 1 day1).

Time frame:
Enrollment up to 2 years
Reported as:
Count of participants · Participants
Overall Response Rate (ORR) in Patients Treated With the Recommended Phase 2 Dose (RP2D)
ParticipantsDose Escalation: Dose Level 0Dose Escalation + Expansion (RP2D): Dose Level 1Dose Escalation: Dose Level 2
Overall Response Rate (ORR) in Patients Treated With the Recommended Phase 2 Dose (RP2D)—3—

Adverse events

Collected over Up to 2 years from treatment start. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation: Dose Level 03/3 (100%)1/3 (33.3%)3/3 (100%)
Dose Escalation + Expansion (RP2D): Dose Level 121/27 (77.8%)10/27 (37%)27/27 (100%)
Dose Escalation: Dose Level 21/2 (50%)0/2 (0%)2/2 (100%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventDose Escalation: Dose Level 0Dose Escalation + Expansion (RP2D): Dose Level 1Dose Escalation: Dose Level 2
Spinal cord compressionNervous system disorders1/30/270/2
StrokeNervous system disorders0/32/270/2
AnemiaBlood and lymphatic system disorders0/31/270/2
Atrial fibrillationCardiac disorders0/31/270/2
Blurred visionEye disorders0/31/270/2
Eye painEye disorders0/31/270/2
Hepatic failureHepatobiliary disorders0/31/270/2
Kidney infectionInfections and infestations0/31/270/2
Urinary tract infectionInfections and infestations0/31/270/2
Injury, poisoning and procedural complications - Other, specifyInjury, poisoning and procedural complications0/31/270/2
Most frequent other events
Showing 10 of 52
Most frequent other events
EventDose Escalation: Dose Level 0Dose Escalation + Expansion (RP2D): Dose Level 1Dose Escalation: Dose Level 2
AnemiaBlood and lymphatic system disorders2/322/272/2
Platelet count decreasedInvestigations1/323/272/2
FatigueGeneral disorders1/317/272/2
Neutrophil count decreasedInvestigations1/314/272/2
NauseaGastrointestinal disorders1/312/271/2
DiarrheaGastrointestinal disorders0/38/271/2
White blood cell decreasedInvestigations1/36/271/2
DizzinessNervous system disorders0/36/271/2
VomitingGastrointestinal disorders1/34/271/2
Back painMusculoskeletal and connective tissue disorders0/34/271/2

Baseline characteristics

Age, Continuous
Age, Continuous(years)Dose Escalation: Dose Level 0Dose Escalation: Dose Level 1Dose Escalation: Dose Level 2Dose Expansion: Dose Level 1Total
Median65 (61 to 70)63 (53 to 81)74 (69 to 79)68 (56 to 81)68 (53 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation: Dose Level 0Dose Escalation: Dose Level 1Dose Escalation: Dose Level 2Dose Expansion: Dose Level 1Total
Female00000
Male3722032
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Escalation: Dose Level 0Dose Escalation: Dose Level 1Dose Escalation: Dose Level 2Dose Expansion: Dose Level 1Total
American Indian or Alaska Native00000
Asian10001
Native Hawaiian or Other Pacific Islander00000
Black or African American00011
White1721929
More than one race10001
Unknown or Not Reported00000
Performance Status by Eastern Cooperative Oncology Group (ECOG) criteria
Performance Status by Eastern Cooperative Oncology Group (ECOG) criteria(Participants)Dose Escalation: Dose Level 0Dose Escalation: Dose Level 1Dose Escalation: Dose Level 2Dose Expansion: Dose Level 1Total
02421220
1130812
08

Study locations

2 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Sep 2025, 50 months.

Results were first posted in Nov 2026, 1 year 1 month after primary completion.

Of 243 non-industry phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 76. This study's 50 months is close to that.

Counting every sponsor, half of 455 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2021
First posted
Apr 15, 2021
StartActual
Jun 28, 2021
Primary completionActual
Sep 25, 2025
CompletionEst.
Dec 30, 2026
Results first posted
Nov 19, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 19, 2026
Primary outcomes
1 edited, 1 time frame changed, 1 description edited
What changed in the outcomes
  • EditedRateNumber of Participants With Dose Limiting Toxicity (DLT)Time frame: Enrollment up to 28 days → Up to 28 days after treatment start (cycle 1)
  • Time frameNumber of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0Enrollment up to 2 years → Up to 2 years from treatment start
  • DescriptionNumber of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0: how it is measured was reworded
Nov 19, 2026
Documents
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedOverall response rateResponse Rate (ORR) in Patients Treated With the Recommended Phase 2 Dose (RP2D)Time frame: Enrollment up to 2 years
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Results posted
    Primary outcomes 1 edited, 1 time frame changed, 1 description edited
    What changed in the outcomes
    • EditedRateNumber of Participants With Dose Limiting Toxicity (DLT)Time frame: Enrollment up to 28 days → Up to 28 days after treatment start (cycle 1)
    • Time frameNumber of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0Enrollment up to 2 years → Up to 2 years from treatment start
    • DescriptionNumber of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0: how it is measured was reworded
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedOverall response rateResponse Rate (ORR) in Patients Treated With the Recommended Phase 2 Dose (RP2D)Time frame: Enrollment up to 2 years
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04846478
Responsible party
Atish Choudhury, MD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Apr 15, 2021
Start date
Jun 28, 2021
Primary completion
Sep 25, 2025
Completion
Dec 30, 2026 (estimated)
Results posted
Nov 19, 2026
Last update
Nov 19, 2026

Study contacts

Atish Choudhury, MD PhD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Talazoparib · Tazemetostat

Start the discussion